Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Cordyceps Sunshine Biotech Holdings Co., Ltd. as of December 31, 2024 is 1.25 MM.
- The operating income for Cordyceps Sunshine Biotech Holdings Co., Ltd. as of December 31, 2024 is -0.18 MM.
- The net income for Cordyceps Sunshine Biotech Holdings Co., Ltd. as of December 31, 2024 is -0.23 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2024-12-31 | 1.25 | -0.18 | -0.23 |
| 2023-12-31 | 0.88 | 0.23 | 0.75 |
| 2023-09-30 | 1.02 | -0.16 | -0.23 |
| 2022-12-31 | 0.45 | -0.42 | -0.72 |
| 2022-09-30 | 0.41 | -0.54 | -0.81 |
| 2022-06-30 | 1.03 | -0.69 | -0.74 |
| 2022-03-31 | 0.95 | -0.59 | -0.61 |
| 2021-12-31 | 0.88 | -0.48 | -0.49 |
| 2020-12-31 | 0.20 | 0.01 | -0.02 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2024-12-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | -0.00 | -0.00 |
| 2022-12-31 | -0.01 | |
| 2022-09-30 | -0.01 | -0.01 |
| 2022-06-30 | -0.01 | -0.01 |
| 2022-03-31 | -0.01 | -0.01 |
| 2021-12-31 | -0.00 | -0.00 |
| 2020-12-31 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Cordyceps Sunshine Biotech Holdings Co., Ltd. as of December 31, 2024 is 0.31 MM.
- The cash from investing activities for Cordyceps Sunshine Biotech Holdings Co., Ltd. as of December 31, 2024 is -0.31 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2024-12-31 | 0.31 | -0.31 | |
| 2023-12-31 | 0.36 | -0.32 | -0.03 |
| 2023-09-30 | 1.48 | -1.54 | -0.07 |
| 2022-12-31 | -0.32 | -0.00 | 0.25 |
| 2022-09-30 | -0.24 | -0.06 | 0.37 |
| 2022-06-30 | -0.25 | -0.12 | 0.37 |
| 2022-03-31 | -0.31 | -0.11 | 0.47 |
| 2021-12-31 | -0.37 | -0.11 | 0.57 |
| 2020-12-31 | -0.20 | -2.25 | 2.45 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2024-12-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2024-12-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2020-12-31 |
Management Effectiveness
- The roa for Cordyceps Sunshine Biotech Holdings Co., Ltd. as of December 31, 2024 is 0.00.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2024-12-31 | 0.00 | ||||
| 2023-12-31 | -12.99 | 0.04 | |||
| 2023-09-30 | -0.25 | ||||
| 2022-12-31 | -0.25 | ||||
| 2022-09-30 | -0.25 | -0.57 | -0.03 | -0.17 | |
| 2022-06-30 | -0.26 | -0.52 | 0.02 | -0.17 | |
| 2022-03-31 | -0.22 | -0.43 | 0.04 | -0.21 | |
| 2021-12-31 | -0.17 | -0.25 | 0.05 | -0.19 | |
| 2020-12-31 | -0.01 | 0.00 | -0.11 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2024-12-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | -0.15 | -1.60 | -1.43 |
| 2022-12-31 | -0.15 | -1.96 | -1.32 |
| 2022-09-30 | -0.15 | -1.96 | -1.32 |
| 2022-06-30 | -0.23 | -0.72 | -0.68 |
| 2022-03-31 | -0.21 | -0.64 | -0.61 |
| 2021-12-31 | -0.20 | -0.56 | -0.54 |
| 2020-12-31 | 0.82 | -0.10 | 0.07 |
Identifiers and Descriptors
| Central Index Key (CIK) |
